Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsFDA grants Breakthrough Therapy Designation for elsunersen in rare pediatric epilepsy
Filed June 22, 2026 · Period ending June 22, 2026 · ~1 min read
Key Changes
-
high
FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222) to treat seizures in SCN2A-DEE, a rare pediatric epilepsy, based on Phase 1/2 trial results showing substantial improvement potential over existing treatments.
Item 8.01 verify on EDGAR → -
high
The designation enables faster development and regulatory review, potentially accelerating time to market for the company's lead drug candidate.
Item 8.01 verify on EDGAR → -
high
BTD was supported by positive topline results from EMBRAVE Part A, a sham-controlled Phase 1/2 study in nine pediatric patients aged 2-12 years with early-seizure-onset SCN2A-DEE.
Item 8.01 verify on EDGAR →
Summary
Praxis announced that the FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222), its antisense oligonucleotide treatment for seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variants. The designation is reserved for therapies demonstrating substantial improvement over existing treatments and provides expedited development and review pathways.
The BTD was supported by positive topline results from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study in nine pediatric patients aged 2-12 years. For retail investors, this represents meaningful regulatory validation of the company's lead asset in a rare pediatric epilepsy indication.
Breakthrough Therapy Designation significantly de-risks the development pathway by providing more frequent FDA interaction and potentially faster approval timelines. While the supporting trial was small with nine patients, the sham-controlled design and positive results were sufficient to convince FDA of the therapy's potential. The company now advances elsunersen with enhanced regulatory support toward later-stage development.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (“DEE”) caused by Gain of Function variants in SCN2A.
The FDA granted Breakthrough Therapy Designation to elsunersen, the company's lead drug candidate for a rare pediatric epilepsy condition. BTD is reserved for therapies showing substantial improvement over existing treatments and enables faster development and regulatory review. This designation significantly de-risks the development pathway and could accelerate time to market.
Added in current filing · verify on EDGAR →
The BTD for elsunersen was supported by positive topline results from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study evaluating ascending doses of elsunersen in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.
The BTD was based on positive results from a small Phase 1/2 trial in nine pediatric patients. While the trial size is limited, the sham-controlled design and positive topline results were sufficient to convince FDA of substantial improvement potential. The company is advancing its lead asset through clinical development with regulatory support.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 3, 2026 · How we verify